SESSION	TOPIC	SPEAKER	COMPANY	TIME
	Registration and Breakfast			7:30-8:30
	Conference Opening	Vibha Jawa	BMS	8:30-8:40
Opening Plenary Lecture	Nonclinical Safety Strategies for Chimeric Antigen T Cell Programs	Kyle Kolaja	BMS	8:40-9:20

SESSION	TOPIC	SPEAKER	COMPANY	TIME
	Session Introduction			9:20-9:25
	Journey of India's First CAR-T Cell Therapy and Its Global Impact	Alka Dwivedi	ImmunoACT	9:25-9:50
	Overcoming Host Rejection in Allogeneic Adoptive Cell Therapy: Engineering Strategies for Persistence and Efficacy	Johannes Stanta	Celerion	9:50-10:15
	Cryo-Fluorescence Tomography: Transformative 3D Imaging to Monitor Gene and Cell Therapies	Matt Silva		10:15-10:40
AM Break				10:40-11:00

SESSION	TOPIC	SPEAKER	COMPANY	TIME
	Session Introduction			11:00-11:05
	AI-Driven Approaches to Enhancing CAR Design	Simon Bornschein	Coding Bio	11:05-11:30
	Translational Development of the GbGm Vector for Sickle Cell Disease: Assessing Safety and Efficacy from Preclinical Models to Human	Mohammad Shadid	Korro Bio	11:30-11:55
	CMC Aspects of ASO Manufacturing	Qingcong Lin		11:55-12:10
Lunch				12:10-1:25

SESSION	TOPIC	SPEAKER	COMPANY	TIME
	Session Introduction			1:25-1:30
	Advanced Bioanalytical Strategies to Determine PK and Biodistribution of Cell and Gene Therapy Products	Salvatore Iovino	Editas Medicine	1:30-1:55
	Harmonizing NAb Sample Testing and Reporting: Key Insights from the White Paper	Jason DelCarpini	Moderna	1:55-2:20
	Bioanalytical Strategies for Cell Therapies: Current Considerations	David Williams	BioAgilytix	2:20-2:45
	Panel Discussion			2:45-3:05
PM Break				3:05-3:25

SESSION	TOPIC	SPEAKER	COMPANY	TIME
	Session Introduction			3:25-3:30
	Making Drugs from T cells: Mathematical Model-informed Design and Deployment of Next Generation T Cell Therapies	Daniel Kirouac	Metrum Research Group	3:30-3:55
	Clinical Pharmacology Considerations in the Development of Allogeneic Cell Therapies - Opportunities & Challenges	Hardik Mody	Genentech	3:55-4:20

SESSION	TOPIC	SPEAKER	COMPANY	TIME
	Session Introduction			4:20-4:25
	CMC Development for Cell and Gene Therapies for the Treatment of β-hemoglobinopathies	Tamara Monesmith	Editas Medicine	4:25-4:50
	Panel Discussion - Andy Lin, Genentech and Tamara Monesmith, Editas			4:50-5:10
Reception				5:10-6:10

SESSION	TOPIC	SPEAKER	COMPANY	TIME
	Registration and Breakfast			8:00-9:00
	Speaker Introduction	Vibha Jawa	BMS	9:00-9:05
Closing Plenary Lecture	From Innovation to Translation to Patients: The Future of Genetically Engineered T-Cells for Human Therapeutics	Bruce Levine	University of Pennsylvania	9:05-9:45

SESSION	TOPIC	SPEAKER	COMPANY	TIME
	Session Introduction			9:45-9:50
	Role of Clinical Pharmacology in Efficient Development of CAR-T Cell Therapy: From FIH Starting Dose Selection to RP2D and Beyond	Indrajeet Singh	J&J	9:50-10:15
	Comprehensive Bioanalytical Cellular Kinetics Strategy for Adoptive T Cell Therapies	Sebastian Guelman	Genentech	10:15-10:40
AM Break				10:40-11:00

SESSION	TOPIC	SPEAKER	COMPANY	TIME
	Session Introduction			11:00-11:05
	Navigating the Regulatory Landscape of Cell Therapies: Nonclinical Considerations	Helen-Marie Dunmore	Certara	11:05-11:30
	Regulatory Expectations and Safety Concerns with CART and Next Generation CART Programs	Gabriela Hernandez-Hoyos	BMS	11:30-11:55
Closing Remarks				11:55-12:00

Sessions

Session I: Current State-of-the-Art Gene Delivery

Session II: Translational PK/PD and Clinical Pharmacology Aspects

Session III: Biomarkers and Clinical Translation Aspects of Gene Therapy

Registration

Click here to register for the Gene and Cell Therapy conference online.

The conference will take place March 20-21, 2025 at:

BMS, Cambridge Crossing, Cambridge, MA

The Boston Society

The Boston Society (R) is an internationally-recognized NON-PROFIT organization dedicated to bringing the best scientific ideas to industrial practice through focused, timely workshops and conferences. 501(c)3

Updates